プレスリリース（日本語） GENEVA AND OSAKA – The Global Antibiotic Research and Development Partnership (GARDP) and Mitsubishi Tanabe Pharma Corporation (MTPC) have signed an … GARDP and Mitsubishi Tanabe Pharma Corporation announce partnership in search for new antibiotics
プレスリリース（日本語） GENEVA AND OSAKA – The Global Antibiotic Research and Development Partnership (GARDP) and Sumitomo Pharma Co., Ltd (Sumitomo Pharma) have signed … GARDP and Sumitomo Pharma announce partnership in search for new antibiotics
Berlin, 17 October 2022 – The German Federal Ministry of Education and Research today announced an additional funding of EUR 50 million to support the … Germany and other funders pledge support to GARDP to ramp up efforts in countering antibiotic resistance
On 16 June, the Global Antibiotic Research and Development Partnership (GARDP) and the National Center for Global Health and Medicine (NCGM) signed a Memorandum of … GARDP and Japan’s National Center for Global Health and Medicine signed an MOU to boost clinical research activities
The Government of Japan has granted additional funding to the Global Antibiotic Research and Development Partnership (GARDP) to support its vital work in developing new … Funding from Government of Japan will boost GARDP’s work in developing new treatments
People around the world are set to benefit from £4.5 million investment from UK Government to develop innovative treatments for drug-resistant infections which cost millions of lives every year.
Osaka (Japan), Geneva (Switzerland), Boston (USA), 15 June 2022 – Shionogi & Co., Ltd. (Shionogi) and the Global Antibiotic Research and Development Partnership (GARDP) have … Shionogi, GARDP and CHAI announce landmark license and collaboration agreements to treat bacterial infections by expanding access to cefiderocol in 135 countries
The Global Antibiotic Research and Development Partnership (GARDP) welcomes funding from the Australian Government to support its critical work in developing and delivering treatments for … GARDP welcomes funding from the Australian Government to boost its critical work to tackle drug-resistant infections
GARDP is pleased to announce funding from the Canton of Geneva to support the development of zoliflodacin, a novel antibiotic currently being assessed through a global phase 3 trial for safety and effectiveness as a treatment for gonorrhoea.
GARDP and the Department of Disease Control of the Thailand Ministry of Public Health (Thai DDC) have signed a Memorandum of Understanding (MOU) to explore opportunities to improve gonorrhea treatment in Thailand, with the intention to develop an access and stewardship strategy to ensure future antibiotics will be available as early as possible in the country.